Health ProductsNotice to Hospitals

Important Safety Information on the Association of Zevalin (ibritumomab tiuxetan) with severe mucocutaneous reactions- Notice to Hospitals- Berlex Canada Inc.

· Published by Health Canada · Official notice

Details

Alert type: Notice to Hospitals
Category: Drugs
Audience: Hospitals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Berlex Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

 
[Text of letter begins]

Notice to Hospitals - Health Canada Endorsed Important Safety Information on Zevalin® (ibritumomab tiuxetan)

December 7, 2005

To Client Institutions,

Please distribute to the relevant Departments of Hematology, Oncology, Radio-oncology, Nuclear Medicine, Dermatology and other involved professional staff and post this Notice in your institution.

Subject: Association of Severe Mucocutaneous Reactions with the ZEVALIN Therapeutic Regimen

ZEVALIN, as part of the ZEVALIN therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Please be aware of the following important safety information that may be relevant for the correct use of ZEVALIN (ibritumomab tiuxetan).

  • Severe mucocutaneous reactions of erythema multiforme, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported postmarketing in association with the administration of the ZEVALIN therapeutic regimen. One of these reactions resulted in a fatal outcome.
  • Patients who develop a severe mucocutaneous reaction should have rituximab and 90Y-ZEVALIN infusions discontinued and receive medical treatment.

Rare cases (3 reports in 3757 patients treated postmarketing = 0.08%) of severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome) have been observed following administration of the ZEVALIN therapeutic regimen, which includes rituximab and radiolabelled ZEVALIN.

After administration of rituximab and ZEVALIN labelled with indium, one patient developed a skin rash.Footnote 1 This rash progressed to toxic epidermal necrolysis after the administration of the second dose of rituximab and ZEVALIN labelled with yttrium. The patient subsequently died of complications. Although the incidence is rare, the fatality associated with the administration of the ZEVALIN therapeutic regimen that included renal failure progressing to death in this case (observed in 1 report of postmarketing experience) is clinically relevant.

Mucocutaneous reactions with a less severe course have occurred up to four months after exposure to the therapeutic regimen of rituximab and ZEVALIN. These cases were the first reported in temporal association with the ZEVALIN therapeutic regimen. Because the ZEVALIN therapeutic regimen includes the use of rituximab, please also consult the prescribing information for RITUXAN (rituximab) for adverse reactions observed with rituximab alone. Considering these findings, Berlex Canada Inc. in collaboration with Health Canada has revised the ZEVALIN Product Monograph. A copy of the revised Product Monograph is included. Since it will take some time until a new Package Insert can be included in the ZEVALIN kits, Berlex wants to inform you as a ZEVALIN prescriber about the new findings in a timely manner.

Patients experiencing a mucocutaneous reaction should not receive any further components of the ZEVALIN therapeutic regimen and should undergo prompt medical evaluation. The safety of re-administration of rituximab or ZEVALIN to patients with any mucocutaneous reaction has not been determined. It should be noted that reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with drug treatments.

The identification, characterization and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of mucocutaneous or other serious or unexpected adverse reactions in patients receiving ZEVALIN should be reported to Berlex Canada Inc. or Health Canada at the following addresses:

Berlex Canada Inc.
334 Avro Avenue
Pointe-Claire, Quebec H9R 5W5
Tel : (800) 361-0240 or Fax: (514) 631-4721

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 1 866 234-2345
Fax: 1 866 678-6789
E-mail: cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738

Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed drug use. Comprehensive information is important to our ability to evaluate the significance of the reported event in association with ZEVALIN.

If you have any questions regarding ZEVALIN, please contact Berlex Canada at 1-800-361-0240.

Yours sincerely,

original signed by

Dr. Jean-Louis Stril, M.D.
Manager, Disease Management and Drug Safety
Berlex Canada Inc.

[Text of letter ends]
 

Footnotes

Footnote 1

Information from a foreign adverse event report. Indium-labelled ZEVALIN is not part of the approved Canadian dosing regimen.

Return to footnote 1 referrer

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime